15th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC)

15th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA) and would be held during Nov 30 - Dec 02, 2017 at Hilton Los Angeles/Universal City, Universal City, California, United States Of America.

The target audience for this medical event for cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dieticians, nurse practitioners, pharmacists, and any other health care professionals who are interested in insulin resistance, diabetes, obesity, cardiovascular disease, and multiple metabolic mechanisms’ effects on health and society, as well as on potential treatment and prevention. This CME Conference has been approved with a maximum of This CME Conference has been approved with a maximum of 27.75 AMA PRA Category 1 Credits.

Course Description:
The Congress is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice, and highlighting our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

? The Congress addresses atherosclerosis, hypertension, and hypercoagulation as well as pharmaceutical interventions like incretins, SGLT2i’s and PCSK9i’s to name a few. The goal is to understand the state of the art pathophysiology and to develop appropriate comprehensive clinical management strategies.

Conference Objectives are :
• Provide comprehensive management of diabetes, by addressing obesity, hypertension, dyslipidemia, and cardiovascular risks.
• Discuss the role of obesity in the development of cardiometabolic conditions
• Discuss the role of incretins in the management of obesity, diabetes, and prevention of CVD
• Be aware of the results of cardiovascular outcome trials and understand the potential role of SGLT2i & GLP1ra in managing Diabetes and CVD
• Evaluate the extent of macrovascular and microvascular disease in diabetes and obesity
• Address the risks of heart disease in patients with diabetes
• Explain the role of lipids, in particular low-density lipoprotien (LDL-C) and non- HDL-C, in the development of atherosclerosis
• Examine the role of PCSK9 and the newly developed monoclonal antibodies- the PCSK9 inhibitors in LDL homeostasis and on the contemporary approaches to management and prevention of CVD
• Describe contemporary approaches to congestive heart failure
• Explain the relationship of the kidney to insulin resistance, diabetes and CVD